Validation of the MiCK Assay (MiCK Assay)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01770665|
Recruitment Status : Terminated (Assay being revised and re-validated.)
First Posted : January 18, 2013
Last Update Posted : September 16, 2016
|Condition or disease|
|Mesothelioma, Small Cell Lung Cancer, NSCLC|
This study will be conducted in two phases.
During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech MiCK assay laboratory to determine the ease of sample acquisition, processing, transport, and assay interpretation.
Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed that the sample acquisition, processing, transport, and assay interpretation are appropriate, we will proceed with the Demonstration Phase.
During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the results will be correlated with prior patient therapy, performance status, and extent of disease.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||21 participants|
|Target Follow-Up Duration:||1 Year|
|Official Title:||Mayo Clinic Validation of the MiCK Assay|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||January 2015|
|Actual Study Completion Date :||September 2016|
|all cancer types|
- Complete response and survival [ Time Frame: 1 year ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01770665
|United States, Minnesota|
|Mayo Validation Support Services 3050 Superior Drive NW|
|Rochester, Minnesota, United States, 55901|
|Study Director:||Mary Karaus||Mayo Clinic|